Core Scientific, Inc. Form 8-K Summary
Business context and reporting period
Core Scientific, Inc. is operating as a debtor-in-possession after the company and certain affiliates filed voluntary Chapter 11 petitions on December 21, 2022, in the U.S. Bankruptcy Court for the Southern District of Texas. The filing reports developments occurring January 31, 2023 and thereafter, including a replacement debtor-in-possession financing facility and monthly operating reports covering December 21–31, 2022.
The company’s common stock and warrants began trading exclusively on the OTC Pink Marketplace on January 3, 2023 under the symbols CORZQ and CRZWQ, respectively.
Financial metrics, financing, and liquidity
- Under the prior DIP facility, the company had utilized $37.5 million of approximately $57.3 million available.
- The replacement DIP facility provides for a non-amortizing, super-priority senior secured term loan facility of up to $70 million.
- $35 million was available after interim Bankruptcy Court approval, with up to an additional $35 million subject to entry of a final DIP order.
- DIP loans bear interest at 10%, payable in kind monthly in arrears.
- The replacement lender will receive a 3.5% upfront commitment fee, payable in kind, and an exit fee equal to 5% of the DIP loans repaid, reduced, or satisfied.
- The stated maturity is December 21, 2023, extendable under specified conditions to March 21, 2024.
- The filing text does not provide clear revenue, profit, cash flow, operating margin, cash balance, total debt, or liquidity figures. The attached monthly operating reports were not included in the provided text.
Material changes versus the prior comparable period
The principal change disclosed is the proposed replacement of the existing DIP facility with financing offering up to $70 million of commitments and different terms. The company also remains in Chapter 11 and its securities now trade on the OTC Pink Marketplace. No comparable-period income statement or cash flow data are provided, so operating changes cannot be quantified.
Guidance, outlook, risks, and unusual items
- The replacement DIP facility was authorized on an interim basis on February 2, 2023; the credit agreement and related documents were still being negotiated and required final Bankruptcy Court approval.
- The facility may terminate if a Chapter 11 plan becomes effective, substantially all assets are sold, the loans are accelerated, an event of default occurs, the cases are dismissed or converted to Chapter 7, or a final DIP order is not entered by March 4, 2023, subject to possible extension by the lender.
- Key risks include failure to obtain final DIP approval or satisfy financing conditions, acceleration of debt, inability to implement a restructuring plan or emerge from Chapter 11, adverse effects on liquidity and operations, increased professional costs, and the outcome and duration of the bankruptcy cases.
- The December monthly operating reports were prepared solely for bankruptcy reporting, were not audited or reviewed, were not prepared in accordance with U.S. GAAP, and may be subject to adjustment and reconciliation.
- Management cautions that the monthly operating reports cover a limited period and may not be indicative of the company’s financial condition, operating results, or future performance.
Most important facts for investors to verify
- Whether the replacement DIP facility received final Bankruptcy Court approval and whether the full additional $35 million became available.
- The final executed DIP credit agreement, including collateral, covenants, default provisions, fees, and maturity extension conditions.
- Actual cash balances, borrowing availability, debt obligations, and cash usage in the December 2022 monthly operating reports and subsequent filings.
- The status and expected timing of a Chapter 11 restructuring plan, asset sale, or emergence from bankruptcy.
- The completeness and reconciliation of the unaudited, non-GAAP monthly operating reports before relying on them for valuation or investment decisions.